Batoprotafib
Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM) . Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].
Product Specifications
CAS Number
1801765-04-7
Product Name Alternative
TNO155
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Phosphatase; SHP2
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/batoprotafib.html
Purity
99.41
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
N[C@@H]1[C@H](C)OCC12CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2
Molecular Formula
C18H24ClN7OS
Molecular Weight
421.95
Precautions
H315, H319, H320
References & Citations
[1]TNO155: SHP2 inhibitor|[2]Liu C, et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin Cancer Res. 2021 Jan 1;27 (1) :342-354.|[3]Weiss A, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12 (6) :1500-1517.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RDSM076 100 Assays
Phosphoenolpyruvate Carboxylase Microplate Assay Kit
Sign In for Pricing
View Details 
LY422018 100 µg
15 Lipoxygenase 2 (ALOX15B) (NM_001039130) Human Over-expression Lysate
Sign In for Pricing
View Details 
